EGFR-tirozinkináz-inhibitorok alkalmazása tüdõrákban: szenzitivitás és rezisztencia

Translated title of the contribution: EGFR tyrosine kinase inhibitors in lung cancer management: Sensitivity and resistance

Moldvay Judit, Peták István

Research output: Contribution to journalArticle

1 Citation (Scopus)


Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.

Original languageHungarian
Pages (from-to)38-49
Number of pages12
JournalMagyar onkologia
Issue number1
Publication statusPublished - 2012


ASJC Scopus subject areas

  • Medicine(all)

Cite this